Literature DB >> 19900249

Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.

Michael Drummond1, Marco Barbieri, John Cook, Henry A Glick, Joanna Lis, Farzana Malik, Shelby D Reed, Frans Rutten, Mark Sculpher, Johan Severens.   

Abstract

ABSTRACT A growing number of jurisdictions now request economic data in support of their decision-making procedures for the pricing and/or reimbursement of health technologies. Because more jurisdictions request economic data, the burden on study sponsors and researchers increases. There are many reasons why the cost-effectiveness of health technologies might vary from place to place. Therefore, this report of an ISPOR Good Practices Task Force reviews what national guidelines for economic evaluation say about transferability, discusses which elements of data could potentially vary from place to place, and recommends good research practices for dealing with aspects of transferability, including strategies based on the analysis of individual patient data and based on decision-analytic modeling.

Entities:  

Mesh:

Year:  2009        PMID: 19900249     DOI: 10.1111/j.1524-4733.2008.00489.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  151 in total

1.  Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.

Authors:  Ties Hoomans; Johan L Severens; Nicole van der Roer; Gepke O Delwel
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  Utilities and QALYs in health economic evaluations: glossary and introduction.

Authors:  Gianni Virgili; Daniela Koleva; Livio Garattini; Rita Banzi; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-07-06       Impact factor: 3.397

3.  Use of economic evaluation in decision making: evidence and recommendations for improvement.

Authors:  Steven Simoens
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

4.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 5.  Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.

Authors:  Dyfrig Hughes; Joanna Charles; Dalia Dawoud; Rhiannon Tudor Edwards; Emily Holmes; Carys Jones; Paul Parham; Catrin Plumpton; Colin Ridyard; Huw Lloyd-Williams; Eifiona Wood; Seow Tien Yeo
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

6.  The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations.

Authors:  Sinaa A Al Aqeel; Mohammed Al-Sultan
Journal:  Saudi Pharm J       Date:  2011-12-24       Impact factor: 4.330

7.  Utilities of the EQ-5D: transferable or not?

Authors:  Saskia Knies; Silvia M A A Evers; Math J J M Candel; Johan L Severens; André J H A Ament
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 8.  Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region.

Authors:  Federico Augustovski; Cynthia Iglesias; Andrea Manca; Michael Drummond; Adolfo Rubinstein; Sebastián García Martí
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 9.  Costs of hospital-acquired infection and transferability of the estimates: a systematic review.

Authors:  H Fukuda; J Lee; Y Imanaka
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

Review 10.  International comparison of cost of falls in older adults living in the community: a systematic review.

Authors:  J C Davis; M C Robertson; M C Ashe; T Liu-Ambrose; K M Khan; C A Marra
Journal:  Osteoporos Int       Date:  2010-02-27       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.